SABINA INTERNATIONAL

Completed

• Conditions: Asthma

• Registration Number: NCT03857178
• Lead Sponsor: AstraZeneca

Brief Summary

The aim of the study is to describe the prescribing pattern of the different types of medications which are used to treat asthma, across multiple countries.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-02-25
• Study First Submitted QC: 2019-02-26
• Study First Posted: 2019-02-27
• Study Start: 2019-03-29
• Primary Completion: 2020-05-06
• Study Completion: 2020-05-06
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-09
• Last Update Posted: 2021-02-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8617

Inclusion Criteria

1. Male and female patients ≥12 years-old
2. Documented diagnosis with Asthma as per medical records.
3. Have had ≥3 consultations with the HCP at study start date
4. After full explanation, a patient or legal guardian must have signed an informed consent document indicating that they understand the purpose of and the procedures required for the study and are willing to participate in the study.

Exclusion Criteria

1. Patient with a diagnosis of chronic obstructive pulmonary disease or other chronic respiratory disease different from Asthma.
2. An acute or chronic condition that, in the investigator's opinion, would limit the patient's ability to participate in this study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The main outcome will be a categorisation of SABA prescription in asthma patients.	12 months retrospective from index date	Mild asthma patients will be categorised into 5 groups according to the number of SABA and ICS prescriptions in the 12 months prior to their index date (initial exposure window): 1. No prescriptions for asthma inhalers; 2. Appropriate SABA prescription with no ICS; 3. Appropriate SABA prescription with ICS; 4. SABA over-prescription with no ICS; 5. SABA over-prescription with ICS; Moderate/severe asthma patients will be categorised into 2 groups according to the number of SABA and ICS prescriptions in the 12 months prior to their index date: 1. Appropriate SABA prescription on top of maintenance therapy; 2. SABA over-prescription on top of maintenance therapy

Trial Locations

Locations (1)

Research Site; 🇦🇷 San Salvador, Argentina